Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Walk and eat to beat pancreatic cancer? tiny trial tests lifestyle fix

NCT ID NCT06712797

Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a 6-month program of exercise tracking and nutrition coaching is practical and acceptable for people with pancreatic cysts that raise cancer risk. Twenty-four participants will use a Fitbit and meet with counselors to increase activity and improve diet. The goal is to see if people stick with the program, not yet to measure cancer prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Physical activity (exercise) and nutrition counseling
What this could lead to
If it works, this could show that a simple lifestyle program helps reduce the risk of pancreatic cancer in people with certain pancreatic cysts.
What could go wrong
This is a very small, early feasibility study with only 24 people. It is designed to see if the program is practical, not to prove it prevents cancer. Results may not apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

Feb 2025

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Endoscopically, radiologically, or biopsy-proven pancreatic intraductal papillary mucinous neoplasm (IPMN) over 15 mm in size * Eastern Cooperative Oncology Group (ECOG) performance status 0-2 * Ability to sign informed consent * Ability to read and speak English or Spanish * Body Mass Index (BMI) greater than or equal to 25 kg/m2 * Visceral obesity based on MRI quantification of visceral and subcutaneous fat; ratio of visceral to subcutaneous fat area greater than 0.4 and/or elevated cytokine, incretin or adipokine biomarkers Exclusion Criteria: * No diagnosis of an IPMN * IPMN with high grade dysplasia, cancer or other high-risk features * Screen failure for exercise safety * Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease * Recent fracture or acute musculoskeletal injury * Numeric pain rating scale of 7 or more out of 10 * Myopathic or rheumatologic disease that impacts physical function

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intraductal papillary mucinous neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pancreatic intraductal papillary-mucinous neoplasm pancreatic neoplasm pancreatic ductal adenocarcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Intraductal papillary mucinous neoplasm Pancreatic ductal adenocarcinoma

Contacts and locations

Locations

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.